A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging.

[1]  Zhaohui Zhu,et al.  Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study , 2023, Theranostics.

[2]  Zhide Guo,et al.  Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin αvβ3 in Various Cancer Types , 2023, The Journal of Nuclear Medicine.

[3]  Jiawei Zhong,et al.  Synthesis and preclinical evaluation of a heterodimeric radioligand targeting fibroblast activation protein and integrin-αvβ3. , 2023, European journal of medicinal chemistry.

[4]  Zhide Guo,et al.  Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD , 2022, Theranostics.

[5]  Hua Wu,et al.  PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study , 2022, The Journal of Nuclear Medicine.

[6]  Jinming Yu,et al.  Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors , 2022, Frontiers in Oncology.

[7]  H. G. van der Poel,et al.  [68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. , 2022, European urology oncology.

[8]  Ganghua Tang,et al.  Automatic Production and Preliminary PET Imaging of a New Imaging Agent [18F]AlF-FAPT , 2022, Frontiers in Oncology.

[9]  Anchisa Kunawudhi,et al.  Head-to-Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study , 2021, The Journal of Nuclear Medicine.

[10]  S. Archibald,et al.  The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules , 2021, EJNMMI Radiopharmacy and Chemistry.

[11]  R. Baum,et al.  Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results , 2021, The Journal of Nuclear Medicine.

[12]  A. Dimitrakopoulou-Strauss,et al.  PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin αvβ3 Receptors , 2021, Molecules.

[13]  Nan Li,et al.  Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  M. Bartholomä,et al.  Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of 64Cu-Labeled Mono- and Trimeric c(RGDfK) Conjugates , 2020, Molecular Imaging and Biology.

[15]  G. Fricker,et al.  Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy , 2020, Pharmaceuticals.

[16]  Torsten Kuwert,et al.  Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor , 2020, The Journal of Nuclear Medicine.

[17]  J. Kaanders,et al.  Imaging angiogenesis in patients with head and neck squamous cell carcinomas by [68Ga]Ga-DOTA-E-[c(RGDfK)]2 PET/CT , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  Z. Savin,et al.  Head-to-Head Comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as a Reference Standard , 2019, The Journal of Nuclear Medicine.

[19]  E. Achten,et al.  Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer , 2019, The Journal of Nuclear Medicine.

[20]  H. Kauczor,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[21]  Xiaoyuan Chen,et al.  18F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study , 2018, The Journal of Nuclear Medicine.

[22]  Shan Zheng,et al.  [99mTc]3PRGD2 for integrin receptor imaging of esophageal cancer: a comparative study with [18F]FDG PET/CT , 2018, Annals of Nuclear Medicine.

[23]  E. Song,et al.  Turning foes to friends: targeting cancer-associated fibroblasts , 2018, Nature Reviews Drug Discovery.

[24]  I. C. Kok,et al.  Molecular Imaging in Cancer Drug Development , 2018, The Journal of Nuclear Medicine.

[25]  H. Hong,et al.  Design and Applications of Bispecific Heterodimers: Molecular Imaging and beyond , 2014, Molecular pharmaceutics.

[26]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[27]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[28]  S. Charlton,et al.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands , 2013, British journal of pharmacology.

[29]  Sanjiv S Gambhir,et al.  A molecular imaging primer: modalities, imaging agents, and applications. , 2012, Physiological reviews.

[30]  Xiaoyuan Chen,et al.  Peptide heterodimers for molecular imaging , 2011, Amino Acids.

[31]  Carlo Chiesa,et al.  EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.